MedDataX Logo

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT ID: NCT01011868

Last Updated: 2014-09-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

494 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

NCT00789035

Diabetes Mellitus, Type 2
COMPLETED PHASE2

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

NCT01257334

Type 2 Diabetes
UNKNOWN PHASE3

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 10773 low dose

Patients receive BI 10773 low dose daily

Group Type EXPERIMENTAL

BI 10773 low dose

Intervention Type DRUG

BI 10773 low dose

BI 10773 high dose

Patients receive BI 10773 high dose daily

Group Type EXPERIMENTAL

BI 10773 placebo

Intervention Type DRUG

BI 10773 placebo

BI 10773 high dose

Intervention Type DRUG

BI 10773 high dose

placebo

Patients receive placebo to match BI 10773 daily

Group Type PLACEBO_COMPARATOR

BI 10773 placebo

Intervention Type DRUG

BI 10773 placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 10773 placebo

BI 10773 placebo

Intervention Type DRUG

BI 10773 low dose

BI 10773 low dose

Intervention Type DRUG

BI 10773 high dose

BI 10773 high dose

Intervention Type DRUG

BI 10773 placebo

BI 10773 placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea.
3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of \>7.0% and \< or = 10% at Visit 1 (screening)
4. Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study)
5. Age \> or =18 years at Visit 1 (screening)
6. BMI \< or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)

Exclusion Criteria

1. Patients with poorly controlled hyperglycemia
2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy
3. MI, stroke, or TIA within 3 months prior to obtaining informed consent
4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias

6\. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1245.33.01014 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1245.33.01047 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Site Status

1245.33.01060 Boehringer Ingelheim Investigational Site

Fresno, California, United States

Site Status

1245.33.01013 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1245.33.01008 Boehringer Ingelheim Investigational Site

Los Gatos, California, United States

Site Status

1245.33.01019 Boehringer Ingelheim Investigational Site

National City, California, United States

Site Status

1245.33.01055 Boehringer Ingelheim Investigational Site

Paramount, California, United States

Site Status

1245.33.01012 Boehringer Ingelheim Investigational Site

Santa Ana, California, United States

Site Status

1245.33.01054 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

1245.33.01046 Boehringer Ingelheim Investigational Site

Bradednton, Florida, United States

Site Status

1245.33.01050 Boehringer Ingelheim Investigational Site

Brooksville, Florida, United States

Site Status

1245.33.01059 Boehringer Ingelheim Investigational Site

Chiefland, Florida, United States

Site Status

1245.33.01028 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

Site Status

1245.33.01029 Boehringer Ingelheim Investigational Site

Fleming Island, Florida, United States

Site Status

1245.33.01048 Boehringer Ingelheim Investigational Site

Hollywood, Florida, United States

Site Status

1245.33.01033 Boehringer Ingelheim Investigational Site

New Port Richey, Florida, United States

Site Status

1245.33.01027 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

1245.33.01040 Boehringer Ingelheim Investigational Site

Decatur, Georgia, United States

Site Status

1245.33.01062 Boehringer Ingelheim Investigational Site

Lawrenceville, Georgia, United States

Site Status

1245.33.01020 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1245.33.01044 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1245.33.01024 Boehringer Ingelheim Investigational Site

Des Moines, Iowa, United States

Site Status

1245.33.01022 Boehringer Ingelheim Investigational Site

Saint Louis, Maryland, United States

Site Status

1245.33.01056 Boehringer Ingelheim Investigational Site

Olive Branch, Mississippi, United States

Site Status

1245.33.01032 Boehringer Ingelheim Investigational Site

Kansas City, Missouri, United States

Site Status

1245.33.01017 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

1245.33.01043 Boehringer Ingelheim Investigational Site

Las Vegas, Nevada, United States

Site Status

1245.33.01051 Boehringer Ingelheim Investigational Site

New Hartford, New York, United States

Site Status

1245.33.01007 Boehringer Ingelheim Investigational Site

Greensboro, North Carolina, United States

Site Status

1245.33.01003 Boehringer Ingelheim Investigational Site

Jacksonville, North Carolina, United States

Site Status

1245.33.01016 Boehringer Ingelheim Investigational Site

Salisbury, North Carolina, United States

Site Status

1245.33.01005 Boehringer Ingelheim Investigational Site

Statesville, North Carolina, United States

Site Status

1245.33.01038 Boehringer Ingelheim Investigational Site

Wilmington, North Carolina, United States

Site Status

1245.33.01026 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

1245.33.01025 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

1245.33.01001 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

1245.33.01031 Boehringer Ingelheim Investigational Site

Tulsa, Oklahoma, United States

Site Status

1245.33.01045 Boehringer Ingelheim Investigational Site

Eugene, Oregon, United States

Site Status

1245.33.01018 Boehringer Ingelheim Investigational Site

Altoona, Pennsylvania, United States

Site Status

1245.33.01041 Boehringer Ingelheim Investigational Site

Carlisle, Pennsylvania, United States

Site Status

1245.33.01042 Boehringer Ingelheim Investigational Site

Landsdale, Pennsylvania, United States

Site Status

1245.33.01004 Boehringer Ingelheim Investigational Site

Greer, South Carolina, United States

Site Status

1245.33.01036 Boehringer Ingelheim Investigational Site

Mt. Pleasant, South Carolina, United States

Site Status

1245.33.01035 Boehringer Ingelheim Investigational Site

Seneca, South Carolina, United States

Site Status

1245.33.01058 Boehringer Ingelheim Investigational Site

Kingsport, Tennessee, United States

Site Status

1245.33.01037 Boehringer Ingelheim Investigational Site

Memphis, Tennessee, United States

Site Status

1245.33.01023 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1245.33.01030 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1245.33.01006 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1245.33.01011 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1245.33.01002 Boehringer Ingelheim Investigational Site

Sugar Land, Texas, United States

Site Status

1245.33.01049 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

1245.33.01015 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

1245.33.01009 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

1245.33.01010 Boehringer Ingelheim Investigational Site

Federal Way, Washington, United States

Site Status

1245.33.01061 Boehringer Ingelheim Investigational Site

Milwaukee, Wisconsin, United States

Site Status

1245.33.45006 Boehringer Ingelheim Investigational Site

Aalborg, , Denmark

Site Status

1245.33.45001 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

Site Status

1245.33.45011 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

Site Status

1245.33.45013 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

Site Status

1245.33.45004 Boehringer Ingelheim Investigational Site

Gentofte Municipality, , Denmark

Site Status

1245.33.45008 Boehringer Ingelheim Investigational Site

Hillerød, , Denmark

Site Status

1245.33.45002 Boehringer Ingelheim Investigational Site

Hvidovre, , Denmark

Site Status

1245.33.45003 Boehringer Ingelheim Investigational Site

København NV, , Denmark

Site Status

1245.33.3301A Boehringer Ingelheim Investigational Site

Bondy, , France

Site Status

1245.33.3302A Boehringer Ingelheim Investigational Site

Corbeil-Essonnes, , France

Site Status

1245.33.3305A Boehringer Ingelheim Investigational Site

La Rochelle, , France

Site Status

1245.33.3306A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

1245.33.3308A Boehringer Ingelheim Investigational Site

Montbrison, , France

Site Status

1245.33.3309A Boehringer Ingelheim Investigational Site

Nanterre, , France

Site Status

1245.33.3310A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

1245.33.3304A Boehringer Ingelheim Investigational Site

Narbonne, , France

Site Status

1245.33.3303A Boehringer Ingelheim Investigational Site

Saint-Mandé, , France

Site Status

1245.33.35302 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

1245.33.35303 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

1245.33.35304 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

1245.33.35104 Boehringer Ingelheim Investigational Site

Aveiro, , Portugal

Site Status

1245.33.35101 Boehringer Ingelheim Investigational Site

Coimbra, , Portugal

Site Status

1245.33.35102 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1245.33.35106 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1245.33.35107 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1245.33.82008 Boehringer Ingelheim Investigational Site

Daejeon, , South Korea

Site Status

1245.33.82007 Boehringer Ingelheim Investigational Site

Gwangju, , South Korea

Site Status

1245.33.82001 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1245.33.82003 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1245.33.82004 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1245.33.82005 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1245.33.82006 Boehringer Ingelheim Investigational Site

Wŏnju, , South Korea

Site Status

1245.33.82002 Boehringer Ingelheim Investigational Site

Yangsan, , South Korea

Site Status

1245.33.44001 Boehringer Ingelheim Investigational Site

Bath, , United Kingdom

Site Status

1245.33.44003 Boehringer Ingelheim Investigational Site

Birmingham, , United Kingdom

Site Status

1245.33.44006 Boehringer Ingelheim Investigational Site

Blackburn, , United Kingdom

Site Status

1245.33.44005 Boehringer Ingelheim Investigational Site

Dorking, , United Kingdom

Site Status

1245.33.44009 Boehringer Ingelheim Investigational Site

Headington, , United Kingdom

Site Status

1245.33.44008 Boehringer Ingelheim Investigational Site

Leicester, , United Kingdom

Site Status

1245.33.44004 Boehringer Ingelheim Investigational Site

Liverpool, , United Kingdom

Site Status

1245.33.44007 Boehringer Ingelheim Investigational Site

Wembley, , United Kingdom

Site Status

1245.33.44002 Boehringer Ingelheim Investigational Site

Whitstable, , United Kingdom

Site Status

1245.33.44010 Boehringer Ingelheim Investigational Site

Wymondham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Denmark France Ireland Portugal South Korea United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.

Reference Type DERIVED
PMID: 35472672 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-013668-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1245.33

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
NCT00602472 COMPLETED PHASE3
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
NCT00601250 COMPLETED PHASE3
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
NCT01167881 COMPLETED PHASE3
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
NCT00328172 COMPLETED PHASE2
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
NCT02150824 COMPLETED PHASE2
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
NCT00740051 COMPLETED PHASE3
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
NCT00309608 COMPLETED PHASE2
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
NCT03138356 COMPLETED PHASE1
Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects
NCT02109679 COMPLETED PHASE1
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
NCT00798161 COMPLETED PHASE3
Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers
NCT02183506 COMPLETED PHASE1
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
NCT01068717 COMPLETED PHASE1
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
NCT00897390 COMPLETED PHASE1
Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects
NCT02173639 COMPLETED PHASE1
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
NCT00899470 COMPLETED PHASE1
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
NCT01211197 COMPLETED PHASE1
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
NCT01068743 COMPLETED PHASE1
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
NCT01778049 COMPLETED PHASE3
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
NCT01215097 COMPLETED PHASE3
A Study of LY2189102 in Patients With Type 2 Diabetes
NCT00942188 COMPLETED PHASE2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
NCT01126580 COMPLETED PHASE3
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
NCT01649297 COMPLETED PHASE2
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
NCT02637037 COMPLETED PHASE1
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
NCT01192152 COMPLETED PHASE1
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00118963 COMPLETED PHASE4